Menu
Search
|

Menu

Close
X

Regenxbio Inc RGNX.OQ (NASDAQ Stock Exchange Global Select Market)

78.57 USD
-0.22 (-0.29%)
As of 12:00 PM EDT
chart
Previous Close 78.80
Open 78.55
Volume 39,623
3m Avg Volume 194,533
Today’s High 79.60
Today’s Low 76.90
52 Week High 85.05
52 Week Low 17.60
Shares Outstanding (mil) 31.94
Market Capitalization (mil) 2,516.56
Forward P/E 56.81
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.14 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
132
FY17
10
FY16
5
FY15
8
EPS (USD)
FY18
3.041
FY17
-2.479
FY16
-2.383
FY15
-0.961
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
56.81
32.89
Price to Sales (TTM)
vs sector
17.68
8.00
Price to Book (MRQ)
vs sector
8.40
4.21
Price to Cash Flow (TTM)
vs sector
44.92
22.15
Total Debt to Equity (MRQ)
vs sector
0.00
17.41
LT Debt to Equity (MRQ)
vs sector
0.00
13.26
Return on Investment (TTM)
vs sector
20.55
13.14
Return on Equity (TTM)
vs sector
20.72
15.15

EXECUTIVE LEADERSHIP

Donald Hayden
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Kenneth Mills
President, Chief Executive Officer, Executive Director, Since 2009
Salary: $514,890.00
Bonus: --
Vittal Vasista
Chief Financial Officer, Since 2017
Salary: $300,000.00
Bonus: $120,000.00
Patrick Christmas
Senior Vice President, General Counsel, Since 2016
Salary: --
Bonus: --
Curran Simpson
Senior Vice President - Technical Operations, Since 2015
Salary: $349,925.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

9600 Blackwell Rd Ste 210
ROCKVILLE   MD   20850-3655

Phone: +1240.5528181

REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.

SPONSORED STORIES